Personnel Information

写真a

NOGAMI Ayako


Job title

Assistant Professor
To the head of this page.▲

Graduating School 【 display / non-display 】

  • Yamaguchi University, Faculty of Medicine, 2007.03, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Tokyo Medical and Dental University, Doctor's Course, Completed

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2011.04
    -
    2015.03
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Graduate Student
  • 2015.04
    -
    2016.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Senior Resident
  • 2016.04
    -
    2017.03
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2017.04
    -
    2018.12
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Central Clinical Facilities， Clinical Laboratory， Assistant Professor
  • 2019.01
    -
    2021.09
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Central Clinical Facilities， Clinical Laboratory， Assistant Professor
  • 2021.10
    -
    2022.03
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Integrated Facilities， Clinical Laboratory， Assistant Professor
  • 2022.04
    -
    2023.04
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Comprehensive Patient Care， Laboratory Medicine， Assistant Professor
  • 2023.05
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Comprehensive Patient Care， Laboratory Medicine， Assistant Professor

▼display all

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Nogami A., Sasaki K.. Therapeutic Advances in Immunotherapies for Hematological Malignancies Therapeutic Advances in Immunotherapies for Hematological Malignancies. International Journal of Molecular Sciences . 2022.09; 23 11526.

  2. Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera. PLoS ONE. 2014; 9 (1): e84746. ( PubMed, DOI )

  3. Motomura, Y; Yoshifuji, K; Tachibana, T; Takase, H; Arai, A; Tanaka, K; Okada, K; Nogami, A; Umezawa, Y; Sakashita, C; Yamamoto, M; Mori, T; Nagao, T. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma BRITISH JOURNAL OF HAEMATOLOGY. 2023.12; ( PubMed, DOI )

  4. Keisuke Tanaka, Ayako Ichikawa, Natsuka Umezawa, Kouhei Yamamoto, Kota Yoshifuji, Keigo Okada, Ayako Nogami, Yoshihiro Umezawa, Toshikage Nagao, Chizuko Sakashita, Takehiko Mori, Shuji Tohda, Ryuji Koike, Shinsuke Yasuda, Masahide Yamamoto. Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis. Cancer Sci. 2023.09; 114 (9): 3719-3727. ( PubMed, DOI )

  5. Nagao T, Yoshifuji K, Sadato D, Motomura Y, Saito M, Yamamoto K, Yamamoto K, Nogami A. Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12. Experimental hematology. 2022.12; 116 37-49. ( PubMed, DOI )

  6. Satoru Aoyama, Shunichiro Yasuda, Huixin Li, Daisuke Watanabe, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Osamu Miura, Norihiko Kawamata. A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells. International Journal of Molecular Medicine. 2022.04; 49 (4): ( PubMed, DOI )

  7. Watanabe D, Nogami A, Okada K, Akiyama H, Umezawa Y, Miura O. FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM. Cancers. 2019.11; 11 (12): ( PubMed, DOI )

  8. Nogami Ayako, Okada Keigo, Ishida Shinya, Akiyama Hiroki, Umezawa Yoshihiro, Miura Osamu. Inhibition of the STAT5/Pim Kinase Axis Enhanecs Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway TRANSLATIONAL ONCOLOGY. 2019.02; 12 (2): 336-349. ( PubMed, DOI )

  9. Akiyama Hiroki, Umezawa Yoshihiro, Ishida Shinya, Okada Keigo, Nogami Ayako, Miura Osamu. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress CANCER LETTERS. 2019; 453 84-94. ( PubMed, DOI )

  10. Ishida S, Akiyama H, Umezawa Y, Okada K, Nogami A, Oshikawa G, Nagao T, Miura O. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget. 2018.06; 9 (42): 26834-26851. ( PubMed, DOI )

  11. Keigo Okada, Ayako Nogami, Shinya Ishida, Hiroki Akiyama, Cheng Chen, Yoshihiro Umezawa and Osamu Miura. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway Oncotarget. 2017.12; 9 8870-8886.

  12. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1). Journal of Biological Chemistry. 2017.12; 292 (48): 19639-19655.

  13. Yoshihiro Umezawa, Tetsuya Kurosu, Hiroki Akiyama, Nang Wu, Ayako Nogami, Toshikage Nagao, Osamu Miusa. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016.06; ( PubMed )

  14. Nogami Ayako, Oshikawa Gaku, Okada Keigo, Fukutake Shusaku, Umezawa Yoshihiro, Nagao Toshikage, Kurosu Tetsuya, Miura Osamu. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget. 2015.04; 6 (11): 9189-9205. ( PubMed )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Establishment of novel Chimeric Antigen Receptor (CAR) improving the target-cell-specificity.. The 85th Annual Meeting of the Japanese Society of Hematology 2023.10.13

  2. 本村 鷹多朗, 吉藤 康太, 貞任 大地, 野上 彩子, 齊藤 真貴子, 岡田 啓五, 青山 慧, 森 毅彦, 長尾 俊景. 新規GCB-DLBCL細胞株TMD13の樹立と特性評価(Establishment and characterization of TMD13. a novel GCB-type DLBCL cell line). 日本リンパ網内系学会会誌 2023.06.01

  3. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Novel protease-mediated double antigen recognizing Chimeric Antigen Receptor (CAR) enhances the directionality of CAR-T cell activity and improves target cell specificity.. Keystone symposia A4: Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy 2023.01.31

  4. Kota Yoshifuji, Yotaro Motomura, Makiko Saito, Ayako Nogami, Genji Kawade, Shiori Watabe, Kouhei Yamamoto, Takahiko Mori, Toshikage Nagao.. TPL2, a New Prognostic Factor and a Potential Therapeutic Target in ABC-DLBCL.. 64th ASH Annual Meeting and Exposition. 2022.12.11 New Orleans

  5. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Novel protease-mediated double antigen recognizing Chimeric Antigen Receptor (CAR) enhances directionality of CAR-T cell activity and improves target cell specificity.. 64th American Society of Hematology (ASH) annual Meeting and Exposition 2022.12.10

  6. Satoru Aoyama, Shunichiro Yasuda, Daisuke Watanabe, Hiroki Akiyama*, Yoshihiro Umezawa, Ayako Nogami, Osamu Miura and Norihiko Kawamat. A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Double Arm” CAR System Improves Tumor-Cell-Specificity of CAR-T Cell Therapy.. The 62nd ASH Annual Meeting and Exposition 2020.12.05 San Diego, California

  7. Daisuke Watanabe, Ayako Nogami, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa:, Toshikage Nagao, Osamu Miura. FLT3-ITD activates RSK1 to upregulate mTORC1 and eIF4B and to inhibit BAD and BIM. The 82nd Annual meeting of Japanese Society of Hematology 2020.10.10

  8. Ayako Nogami, Watanabe Daisuke, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohdaand Osamu Miura. FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim. 60th ASH Annual Meeting and Exposition 2019.12.01 FL, Orange County Convention Center

  9. Ayako Nogami, Keigo Okada, Daisuke Watanabe, Hiroki Akiyama, Yoshihiro Umezawa, Shinya Ishida, Gaku Oshikawa, Shuji Tohda, Osamu Miura . Proteasome Inhibitors Downregulate the mTORC1/4EBP1/S6K/Mcl-1 Pathway Cooperatively with Inhibitors for The STAT5/Pim Kinase Pathway to Induce Apoptosis in FLT3-ITD-positive AML Cells. The 9th JSH International Symposium 2018 2018.07.28 Kyoto

  10. Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Shinya Ishida, Ayako Nogami, and Osamu Miura. Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells. 59th ASH Annual Meeting & Exposition 2017.12.17 Atlanta, GA, USA

  11. Tomoko Yamashita, Hiroki Tsutsumi, Kota Yoshifuji, Tatsuya Saito, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Toshikage Nagao, Chizduko Sakashita, Masahide Yamamoto, Ayako Arai, Norihiko Kawamata, Osamu Miura, Tetsuya Fukuda. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 11q Deletion. 第79回日本血液学会学術集会 2017.10.22

  12. Keigo Okada, Ayako Nogami, Cheng Chen, Maho kawakami, Hiroki Akiyama, Shinya Ishida, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by enhancing mTORC1/Mcl-1 pathway via Pim kinase. 第79回日本血液学会学術集会 2017.10.20

  13. Hiroki Akiyama，Yoshihiro Umezawa，Keigo Okada，Shinya Ishida，Ayako Nogami，Gaku Oshikawa，Osamu Miura. Deubiquitinase inhibitor WP1130 blocks JAK2-V617F and FLT3-ITD to induce apoptosis in leukemic cells. 第78回日本血液学会学術集会 2016.10.15 横浜

  14. Ayako Nogami, Keigo Okada, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa,Tetsuya Kurosu,Osamu Miura. FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression. 57th ASH Annual Meeting and Exposition 2015.12.05 Orange County Convention Center, Orlando

  15. Keigo Okada, Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by inducing Pim kinases through STAT5 activation. 第77回日本血液学会学術集会 2015.10.18

  16. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. PECAM−1 enhances SDF-1-induced chemotaxis mediated through activation of the PI3K/Akt/mTORC1 pathway. The 77th annual meeting of the japanese society of hematology 2015.10.17

▼display all

To the head of this page.▲